4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000112
PRESIDENT AND CFO sold 8,000 shares at an average $85.81 ($686,518)
- PRESIDENT AND CFO acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-11-18 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 117,491 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-11-18 | Sale 10b5-1 | −6,111 | $85.60 | $523,071 | 111,380 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-11-18 | Sale 10b5-1 | −1,757 | $86.49 | $151,956 | 109,623 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-11-18 | Sale 10b5-1 | −132 | $87.05 | $11,491 | 109,491 | D |
| Derivatives | |||||||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-11-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 270,827 | D | ||
| Open-market sales · 8,000 sh · avg $85.81 · $686,518 | |||||||
Loading xslF345X05/wk-form4_1732052574.xml…